Systematic drug perturbations on cancer cells reveal diverse exit paths from proliferative state

Area of Science:

• Cellular dynamics
• Cancer biology
• Systems biology

Background:

• Cell state transitions are dynamic processes, often described by gene expression trajectories.
• Understanding cancer cell proliferation is crucial for developing effective therapies.
• Traditional pathway analysis can be complemented by dynamical systems approaches.

Purpose of the Study:

• To identify compounds that can induce breast cancer cells to exit a proliferative state.
• To investigate the underlying molecular mechanisms and signaling pathways involved in drug-induced cell-state transitions.
• To explore the utility of multi-trajectory analysis in understanding therapeutic cell-state switching.

Main Methods:

• Screening of a drug library for non-cytotoxic compounds that induce differentiation in MCF7 breast cancer cells.
• Transcriptome analysis to map cell state transition trajectories.
• Network analysis of targeted pathways to identify common molecular mechanisms.
• Comparative analysis of chemical structures and drug targets.

Main Results:

• Identified 16 non-cytotoxic compounds that stimulate MCF7 cells to transition from a proliferative to a differentiated state.
• Observed that drug-induced transcriptome trajectories diverged and then converged.
• Found minimal overlap in chemical structures and direct drug targets of the identified compounds.
• Network analysis revealed a core signaling pathway involving stress response and STAT1 down-regulation preceding differentiation.

Conclusions:

• A combination of drug perturbations and pathway analysis provides a comprehensive view of cell-state transition dynamics.
• Common stress-response pathways and STAT1 down-regulation are key events in therapeutically induced differentiation of breast cancer cells.
• This multi-trajectory approach offers insights into overcoming resistance to cell-state switching in cancer therapy.